Novavax Launches Clinical Trial for JN.1 Subvariant COVID-19 Vaccine
Novavax initiates a new clinical trial to evaluate the safety and immunogenicity of its JN.1 subvariant vaccine (NVX CoV2705) with Matrix-M adjuvant. The study will compare results with the previously authorized NVX-CoV2601 vaccine, marking a significant step in addressing emerging COVID-19 variants.
© Copyright 2025. All Rights Reserved by MedPath